Results 71 to 80 of about 88,666 (249)

The Tribble with APL: a new road to therapy [PDF]

, 2017
The t(15;17) translocation generates a PML-RARα fusion protein causative for acute promyelocytic leukemia (APL). Li et al. now identify the pseudokinase stress protein TRIB3 as an important factor in APL disease progression and therapy resistance ...
Carmody, Ruaidhri, Keeshan, Karen
core   +1 more source

ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma

The FEBS Journal, EarlyView.
KRAB zinc finger protein ZNF224 acts as an oncogenic factor in melanoma cells, enhancing p21 cytosolic retention and impairing nuclear p21 cytostatic activity through stimulation of the AKT pathway. Furthermore, ZNF224 regulates transcriptional expression levels of p21 via p53.
Leandra Sepe, Umberto Candia, Dario Sasso del Verme, Elvira Toscano, Marianna Toriello, Gaetano Sodaro, Roberta Rapuano, Simona Romano, Michela Grosso, Giovanni Paolella, Angelo Lupo, Paola Costanzo, Elena Cesaro   +12 more
wiley   +1 more source

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

A case of chronic myelogenous leukemia in pregnancy characterized by a complex translocation t(9;22;11)(q34;q11.2;q13)

Hematology Reports, 2011
The management of chronic myelogenous leukemia during pregnancy requires balancing the well-being of the mother with that of the fetus. We report a case of a 26-year-old lady who was diagnosed with chronic myelogenous leukemia (CML) at 15 weeks gestation
Surachit Kumar, Mariya Apostolova, Paul V. Woolley   +2 more
doaj   +1 more source

Targeting quiescent leukemic stem cells using second generation autophagy inhibitors [PDF]

, 2019
In chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) treatment induces autophagy that promotes survival and TKI-resistance in leukemic stem cells (LSCs).
A Hamilton, A Kuma, AS Corbin, B Ronan, B Zhang, B Zhang, BJ Druker, C Bellodi, D Mahalingam, DJ Klionsky, DT Vogl, E Weisberg, F Liu, G Karsli-Uzunbas, JD Mancias, JY Guo, JY Guo, M Karvela, M Komatsu, M Mortensen, M Schemionek, MR Rosenfeld, MR Warr, MT Rosenfeldt, N Mizushima, P Rousselot, Q McAfee, R Bago, R Rangwala, R Rangwala, S Brenner, S Kimura, S Koschmieder, SM Graham, T Holyoake, TL Holyoake, TL Holyoake, TT Ho, V Kirkin, VW Rebecca, WE Dowdle, XH Ma, Z Tothova   +42 more
core   +2 more sources

How I Approach Ethical Considerations for Pediatric Phase I CAR T‐Cell Trials

Pediatric Blood &Cancer, Volume 72, Issue 8, August 2025.
ABSTRACT Phase I trials of chimeric antigen receptor (CAR) T cells have shown remarkable promise in pediatric B‐cell malignancies. Such outcomes have shifted expectations for other phase I CAR T‐cell trials to have high response rates. The juxtaposition of high expectations, uncertain outcomes, and potential for life‐threatening toxicities raises ...
Sarah W. Peters, Sara K. Silbert, Elizabeth M. Holland, Annette Rid, Rayne H. Rouce, Christine Grady, Nirali N. Shah   +6 more
wiley   +1 more source

Multi‐Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations

Pharmacology Research &Perspectives, Volume 13, Issue 4, August 2025.
ABSTRACT Alzheimer's disease (AD) is a complex and multifactorial neurodegenerative disorder, recognized as the most prevalent form of dementia. It is characterized by multiple pathological processes, including amyloid‐beta accumulation, neurofibrillary tangles, and neuroinflammation. The therapeutic efficacy of traditional single‐target drugs has been
Md Saad Hossain, Md Hamed Hussain
wiley   +1 more source

A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report

SAGE Open Medical Case Reports, 2018
Bosutinib is a BCR-ABL tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome–positive chronic myelogenous leukemia. We report a case of bosutinib-induced interstitial granulomatous drug reaction in a 50-year-old Caucasian female
Alexander B Aria, Leon Chen, Auris O Huen   +2 more
doaj   +1 more source

Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. [PDF]

, 2017
The effect of prior malignancy on the risk of developing, and prognosis of, acute lymphoblastic leukemia (ALL) is unknown. This observational study utilized the California Cancer Registry to estimate the risk of developing ALL after a prior malignancy ...
Brunson, A, Jonas, BA, Keegan, THM, Paulus, JK, Rosenberg, AS, Tuscano, J, Wun, T   +6 more
core   +2 more sources

PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis

Journal of Medical Virology, Volume 97, Issue 7, July 2025.
ABSTRACT PARP1 has been shown to regulate EBV latency. However, the therapeutic effect of PARP1 inhibitors on EBV+ lymphomagenesis has not yet been explored. Here, we show that PARPi BMN 673 has a potent antitumor effect on EBV‐driven LCL in a mouse xenograft model. We found that PARP1 inhibition induces a dramatic transcriptional reprogramming of LCLs
Lisa Beatrice Caruso, Giorgia Napoletani, Samantha S. Soldan, Davide Maestri, Toshitha Kannan, Sarah Preston‐Alp, Peter Vogel, Andrew Kossenkov, Asher Sobotka, Paul M. Lieberman, Italo Tempera   +10 more
wiley   +1 more source